We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Exact Sciences (EXAS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Exact Sciences is one of 883 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. EXAS is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for EXAS's full-year earnings has moved 6.47% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that EXAS has returned about 53.69% since the start of the calendar year. At the same time, Medical stocks have gained an average of 11.36%. This means that Exact Sciences is outperforming the sector as a whole this year.
Looking more specifically, EXAS belongs to the Medical - Biomedical and Genetics industry, a group that includes 374 individual stocks and currently sits at #64 in the Zacks Industry Rank. On average, stocks in this group have gained 10.74% this year, meaning that EXAS is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on EXAS as it attempts to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Exact Sciences (EXAS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Exact Sciences is one of 883 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. EXAS is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for EXAS's full-year earnings has moved 6.47% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that EXAS has returned about 53.69% since the start of the calendar year. At the same time, Medical stocks have gained an average of 11.36%. This means that Exact Sciences is outperforming the sector as a whole this year.
Looking more specifically, EXAS belongs to the Medical - Biomedical and Genetics industry, a group that includes 374 individual stocks and currently sits at #64 in the Zacks Industry Rank. On average, stocks in this group have gained 10.74% this year, meaning that EXAS is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on EXAS as it attempts to continue its solid performance.